TOP TEN perturbations for 1446_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1446_at
Selected probe(set): 201316_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1446_at (201316_at) across 6673 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-3.1989002
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-2.9242039
Number of Samples:13 / 2
Experimental ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):2.8409557
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-2.2847548
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).

house dust mite study 2 (allergic) / house dust mite study 2 (non-allergic)

Relative Expression (log2-ratio):-2.0818777
Number of Samples:5 / 4
Experimental house dust mite study 2 (allergic)
Primary nasal epithelial cells from subjects with monotypical allergy to house dust mite (HDM) were exposed to house dust mite extract (2µg/ml) for 24 hours. Subjects (19-55 years old) were selected based on skin prick test for HDM and other common allergens. The subjects had refrained from using any medication for their allergy in the 4 weeks before the samples collection. Nasal biopsies for isolation of primary cells were taken from the lower edge of the inferior turbinate, and 2 cm from the anterior end.
Control house dust mite study 2 (non-allergic)
Primary nasal epithelial cells from healthy subjects with no allergies were exposed to house dust mite (HDM) extract (2µg/ml) for 24 hours. Subjects (21-32 years old) were selected based on skin prick test for HDM and other common allergens. Nasal biopsies for isolation of primary cells were taken from the lower edge of the inferior turbinate, and 2 cm from the anterior end.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)

Relative Expression (log2-ratio):1.9858627
Number of Samples:2 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted).

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):1.923048
Number of Samples:4 / 8
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary)

Relative Expression (log2-ratio):1.8606701
Number of Samples:2 / 5
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, dedifferentiated liposarcoma of the soft tissue (subcutaneously implanted).

collecting duct carcinoma study 1 / normal kidney tissue

Relative Expression (log2-ratio):-1.7867622
Number of Samples:2 / 2
Experimental collecting duct carcinoma study 1
Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC).
Control normal kidney tissue
Normal fetal kidney tissue samples.

dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):1.7689667
Number of Samples:7 / 8
Experimental dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

Organism: Homo sapiens
Gene: 1446_at
Selected probe(set): 201317_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1446_at (201317_s_at) across 6673 perturbations tested by GENEVESTIGATOR:

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-2.596367
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

T-cell activation study 4 / normal resting T-cell sample

Relative Expression (log2-ratio):2.5069122
Number of Samples:2 / 2
Experimental T-cell activation study 4
T-cell samples antiCD3 activated for 30hrs.
Control normal resting T-cell sample
T cells resting for 30h.

Alzheimer's disease study 9 / normal pyramidal neuron (posterior cingulate)

Relative Expression (log2-ratio):-1.9996243
Number of Samples:9 / 13
Experimental Alzheimer's disease study 9
Cortical layer III pyramidal neurons of the posterior cingulate of clinically and neuropathologically classified late-onset Alzheimer´s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent.
Control normal pyramidal neuron (posterior cingulate)
Cortical layer III pyramidal neurons of the posterior cingulate of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density.

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):1.9848576
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):1.9545641
Number of Samples:3 / 3
Experimental glioma study 17 (glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):1.9387875
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)

Relative Expression (log2-ratio):-1.9290476
Number of Samples:3 / 11
Experimental HCC study 20 (CDX; Hep-G2; ectopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; ectopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.

colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; lung)

Relative Expression (log2-ratio):-1.9078951
Number of Samples:2 / 5
Experimental colorectal cancer study 43 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma.
Control colorectal cancer study 43 (metastase; lung)
Metastatic tumor tissue obtained from the lung of patients with primary colon adenocarcinoma.

ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-1.9050493
Number of Samples:13 / 2
Experimental ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).

septic shock study 3 (D2; non-survivor) / normal blood sample

Relative Expression (log2-ratio):1.9027643
Number of Samples:8 / 22
Experimental septic shock study 3 (D2; non-survivor)
Blood samples from patients (non-survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.